These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31279874)

  • 1. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
    Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
    Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
    Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
    J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
    Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
    Hashmi AA; Hussain ZF; Irfan M; Edhi MM; Kanwal S; Faridi N; Khan A
    BMC Res Notes; 2018 Mar; 11(1):207. PubMed ID: 29587848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
    Bontoux C; Rialland T; Cussenot O; Compérat E
    Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    Muilwijk T; Akand M; Daelemans S; Marien K; Waumans Y; Kockx M; Baekelandt L; Van den Broeck T; Van der Aa F; Gevaert T; Joniau S
    PLoS One; 2021; 16(9):e0257195. PubMed ID: 34525114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases.
    Solano-Iturri JD; Beitia M; Errarte P; Calvete-Candenas J; Etxezarraga MC; Loizate A; Echevarria E; Badiola I; Larrinaga G
    Aging (Albany NY); 2020 May; 12(11):10337-10358. PubMed ID: 32428869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
    Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.
    Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC
    Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
    Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
    Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.